Changes in an her-2 peptide upregulating hla-a2 expression affect both conformational epitopes and ctl recognition: Implications for optimization of antigen presentation and tumor-specific ctl induction

Journal of Immunotherapy

Volumn 18, Issue 4, 1995, Pages 197-209

  Fisk, Bryan ^a   Savary, Cherylyn ^a   Hudson, J Michael ^a   O'Brian, Catherine A ^a   Murray, James L ^a   Wharton, J Taylor ^a   Ioannides, Constantin G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; CTL; HER 2; Optimization; Presentation

Indexed keywords

EPITOPE; FOLATE BINDING PROTEIN; PEPTIDE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION REGULATION; HLA SYSTEM; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; OVARY TUMOR; PRIORITY JOURNAL; REGULATORY MECHANISM;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 0029555751     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199511000-00001     Document Type: Article

References (41)

1. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U.S.A. 1994;91:6458-62.
2. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
3. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
4. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2- restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
5. Ioannides CG, Fisk B, Fan D, Biddison WA, Wharton JT, O’Brian CA. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993;151:225-34.
6. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor specific CTL lines. J Exp Med 1995;181:2709-17.
7. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-6.
8. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of MHC class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by non-dominant anchor residues. J Exp Med 1994;180:1471-83.
9. Fisk B, Chesak B, Ioannides MG, Wharton JT, Ioannides CG. Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2. Int J Oncol 1994;5: 51-63.
10. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-67.
11. Catipovic B, Del Porto J, Mage M, Johansen TE, Schneck JP. Major histocompatibility complex conformational epitopes are peptide specific. J Exp Med 1992;176:1611-8.
12. Chen W, Fecondo J, McCluskey J. The structural influence of individual residues located within peptide antigen depends upon their sequence context. Mol Immunol 1994;31:1069-75.
13. Fisk B, Chesak B. Pollack M, Wharton JT, Ioannides CG. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 1994;157:412-27.
14. Salter RD, Creswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant T × B cell hybrid. EMBO J 1986;5:943-9.
15. Salter RD, Clayberger C, Lomen CE, et al. In vitro mutagenesis at a single residue introduces B and T cell epitopes into a class I HLA molecule. J Exp Med 1987;166:283-8.
16. Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol 1988;141:2811-8.
17. Hogan KT, Clayberger C, Bernhard EJ, et al. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2 specific antibodies and cytotoxic T lymphocytes. J Immunol 1989;142:2097-104.
18. Rohren EM, McCormick DJ, Pease LR. Peptide-induced conformational changes in class I molecules. J Immunol 1991;152:5337-43.
19. Bluestone JA, Jameson S, Miller S, Dick R II. Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition. J Exp Med 1992;176:1757-61.
20. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of selfpeptides eluted from MHC molecules. Nature 1991;351:290-6.
21. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
22. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994;12:181-207.
23. Henderson RA, Michel H, Sakaguchi K, et al. HLA- A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992;255:1264-6.
24. Lanzavecchia A, Watts C. Peptide partners call the tune. Nature 1994;371:198-9.
25. Townsend A, Elliott T, Cerundolo V, Foster L, Barber B, Tse A. Assembly of MHC class I molecules analyzed in vitro. Cell 1990;62:285-95.
26. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-708.
27. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 1994;371:626-9.
28. Boivier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 1994;265:398-402.
29. Bednarek MA, Sauma SY, Gammon MC, et al. The minimum peptide epitope from the influenza virus matrix protein: extra and intracellular loading of HLA-A2. J Immunol 1991;147:4047-53.
30. Hogquist KA, Grandea AG III, Bevan MJ. Peptide variants reveal how antibodies recognize major histocompatibility complex class I. Eur J Immunol 1993;23:2072-7.
31. Griem P, Wallny H-J, Falk K, et al. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 1991;65:633-40.
32. Neisig A, Roelse J, Sijts AJ, et al. Major differences in transporter associated with antigen presentation (TAP)- dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol 1995;154:1273-9.
33. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.
34. Ioannides CG, Ioannides MG, O’Brian CA. T cell recognition of oncogene products, a new strategy for immunotherapy. Mol Carcinog 1992;6:77-81.
35. Schild H, Norda M, Deres K, et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J Exp Med 1991;174:1665-8.
36. Kageyama S, Tsomides TJ, Sykulev Y, Eisen H. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154:567-76.
37. Udaka K, Wiesmuller KH, Kienle S, Jung G, Walden P. Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries. J Exp Med 1995;181:2097-108.
38. Eisen HN. General immunology. Philadelphia: JB Lippincott, 1990.
39. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993;177:989-98.
40. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995;154:3991-8.
41. Ioannides CG, Platsoucas D, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257-66.